| RS2143532950 |
ITGB4
|
Health Risk |
Pathogenic |
Junctional epidermolysis bullosa with pyloric atresia, Junctional epidermolysis bullosa with pyloric atresia |
| RS2143534611 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2143538802 |
BCAS3
|
Health Risk |
Likely pathogenic |
Global developmental delay, Global developmental delay |
| RS2143555720 |
LOXHD1
|
Health Risk |
Pathogenic |
— |
| RS2143556646 |
CLTC
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 56 |
| RS2143559471 |
LOXHD1
|
Health Risk |
Likely pathogenic |
— |
| RS2143561043 |
CLTC
|
Health Risk |
Pathogenic |
— |
| RS2143562536 |
ELAC2
|
Health Risk |
Pathogenic |
Combined oxidative phosphorylation defect type 17, Combined oxidative phosphorylation defect type 17 |
| RS2143570702 |
SMCHD1
|
Health Risk |
Pathogenic |
Facioscapulohumeral muscular dystrophy 2, Facioscapulohumeral muscular dystrophy 2 |
| RS2143577004 |
SETD1A
|
Health Risk |
Likely pathogenic |
— |
| RS2143577665 |
CCDC40
|
Health Risk |
Pathogenic |
Primary ciliary dyskinesia, Primary ciliary dyskinesia |
| RS2143580660 |
CLTC
|
Health Risk |
Pathogenic |
Autosomal dominant non-syndromic intellectual disability, Intellectual disability |
| RS2143585058 |
FANCA
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia, Fanconi anemia |
| RS2143585254 |
GALK1
|
Health Risk |
Pathogenic |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS2143585362 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2143586491 |
CLTC
|
Health Risk |
Pathogenic |
— |
| RS2143586633 |
GALK1
|
Health Risk |
Likely pathogenic |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS2143589664 |
SETD1A
|
Health Risk |
Conflicting classifications of pathogenicity |
Epilepsy, early-onset |
| RS2143591648 |
JUP
|
Health Risk |
Likely pathogenic |
Naxos disease, Arrhythmogenic right ventricular dysplasia 12 |
| RS2143591718 |
CLTC
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal dominant 56 |
| RS2143592085 |
JUP
|
Health Risk |
Likely pathogenic |
— |
| RS2143592425 |
CLTC
|
Health Risk |
Likely pathogenic |
Neurodevelopmental disorder, Neurodevelopmental disorder |
| RS2143593640 |
CLTC
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 56 |
| RS2143594831 |
CLTC
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 56 |
| RS2143595030 |
CLTC
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 56 |
| RS2143596526 |
CLTC
|
Health Risk |
Pathogenic |
— |
| RS2143597221 |
CLTC
|
Health Risk |
Likely pathogenic |
— |
| RS2143600670 |
CLTC
|
Health Risk |
Likely pathogenic |
See cases, See cases |
| RS2143601360 |
GALK1
|
Health Risk |
Pathogenic |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS2143602282 |
CLTC
|
Health Risk |
Pathogenic |
— |
| RS2143602393 |
CLTC
|
Health Risk |
Pathogenic |
Abnormal corpus callosum morphology, Abnormal corpus callosum morphology |
| RS2143603585 |
GALK1
|
Health Risk |
Likely pathogenic |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS2143605190 |
GALK1
|
Health Risk |
Pathogenic/Likely pathogenic |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS2143605351 |
GALK1
|
Health Risk |
Likely pathogenic |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS2143607002 |
ELAC2
|
Health Risk |
Likely pathogenic |
Combined oxidative phosphorylation defect type 17, Combined oxidative phosphorylation defect type 17 |
| RS2143608028 |
GALK1
|
Health Risk |
Pathogenic |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS2143608501 |
GALK1
|
Health Risk |
Pathogenic |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS2143608720 |
GALK1
|
Health Risk |
Pathogenic |
Deficiency of galactokinase, Deficiency of galactokinase |
| RS2143615250 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2143615845 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2143616842 |
SMCHD1
|
Health Risk |
Pathogenic |
— |
| RS2143625205 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2143625237 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143625250 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143625360 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143625553 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143625661 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143625963 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143626114 |
NF1
|
Health Risk |
Pathogenic |
Cardiovascular phenotype, Hereditary cancer-predisposing syndrome |
| RS2143626219 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143626256 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143626487 |
NF1
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurofibromatosis, type 1 |
| RS2143626686 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143626844 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143627085 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143627187 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2143627506 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143627564 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143627611 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143629918 |
H3-3B
|
Health Risk |
Likely pathogenic |
Intellectual disability, Global developmental delay |
| RS2143629984 |
H3-3B
|
Health Risk |
Pathogenic/Likely pathogenic |
Bryant-Li-Bhoj neurodevelopmental syndrome 2, H3-3B-related disorder |
| RS2143629995 |
H3-3B
|
Health Risk |
Pathogenic |
Bryant-Li-Bhoj neurodevelopmental syndrome 2, Bryant-Li-Bhoj neurodevelopmental syndrome 2 |
| RS2143630846 |
H3-3B
|
Health Risk |
Pathogenic/Likely pathogenic |
Intellectual disability, Global developmental delay |
| RS2143631260 |
H3-3B
|
Health Risk |
Pathogenic/Likely pathogenic |
Neurodevelopmental disorder, Neurodevelopmental disorder |
| RS2143631293 |
H3-3B
|
Health Risk |
Pathogenic |
Bryant-Li-Bhoj neurodevelopmental syndrome 2, Bryant-Li-Bhoj neurodevelopmental syndrome 2 |
| RS2143631320 |
H3-3B
|
Health Risk |
Likely pathogenic |
Intellectual disability, Global developmental delay |
| RS2143631386 |
MAP3K3
|
Health Risk |
Pathogenic/Likely pathogenic |
Verrucous hemangioma, CEREBRAL CAVERNOUS MALFORMATIONS 5 |
| RS2143631409 |
H3-3B
|
Health Risk |
Pathogenic |
— |
| RS2143631415 |
H3-3B
|
Health Risk |
Likely pathogenic |
Brain imaging abnormality, Delayed speech and language development |
| RS2143632135 |
FANCA
|
Health Risk |
Conflicting classifications of pathogenicity |
Ovarian cancer, Fanconi anemia complementation group A |
| RS2143632171 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia, Fanconi anemia |
| RS2143632512 |
SMCHD1
|
Health Risk |
Pathogenic |
Proximal upper limb muscle weakness, Proximal upper limb muscle weakness |
| RS2143641088 |
HSD3B7
|
Health Risk |
Pathogenic |
— |
| RS2143644450 |
CNTNAP1
|
Health Risk |
Likely pathogenic |
— |
| RS2143645089 |
NF1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neurofibromatosis, type 1 |
| RS2143645748 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143645855 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143645885 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143645944 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143646047 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143646085 |
NF1
|
Health Risk |
Pathogenic |
— |
| RS2143646186 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143646461 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143646665 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143646778 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2143647375 |
GNAO1
|
Health Risk |
Likely pathogenic |
Early-infantile DEE, Early-infantile DEE |
| RS2143647637 |
SP6
|
Health Risk |
Pathogenic |
Amelogenesis imperfecta, IIa 1K |
| RS2143650879 |
GNAL
|
Health Risk |
Pathogenic |
Dystonic disorder, Dystonic disorder |
| RS2143651415 |
JUP
|
Health Risk |
Pathogenic |
Naxos disease, Arrhythmogenic right ventricular dysplasia 12 |
| RS2143651895 |
PRKAR1A
|
Health Risk |
Likely pathogenic |
— |
| RS2143654921 |
HYDIN
|
Health Risk |
Pathogenic |
Primary ciliary dyskinesia, Primary ciliary dyskinesia |
| RS2143656696 |
FANCA
|
Health Risk |
Likely pathogenic |
Fanconi anemia, Fanconi anemia complementation group A |
| RS2143657184 |
FANCA
|
Health Risk |
Pathogenic |
Fanconi anemia complementation group A, Fanconi anemia complementation group A |
| RS2143657729 |
FANCA
|
Health Risk |
Conflicting classifications of pathogenicity |
Fanconi anemia, Fanconi anemia |
| RS2143660403 |
GNAO1
|
Health Risk |
Pathogenic |
Neurodevelopmental disorder with involuntary movements, Developmental and epileptic encephalopathy |
| RS2143661323 |
CNTNAP1
|
Health Risk |
Likely pathogenic |
Lethal congenital contracture syndrome 7, Lethal congenital contracture syndrome 7 |
| RS2143661479 |
STX1B
|
Health Risk |
Likely pathogenic |
Epileptic encephalopathy, Epileptic encephalopathy |
| RS2143661528 |
STX1B
|
Health Risk |
Likely pathogenic |
Generalized epilepsy with febrile seizures plus, type 9 |
| RS2143663531 |
CNTNAP1
|
Health Risk |
Pathogenic |
— |
| RS2143663891 |
CNTNAP1
|
Health Risk |
Conflicting classifications of pathogenicity |
Neuropathy, congenital hypomyelinating |